These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 32359682)

  • 41. Dietary Supplement Therapies for Inflammatory Bowel Disease: Crohn's Disease and Ulcerative Colitis.
    Parian A; Limketkai BN
    Curr Pharm Des; 2016; 22(2):180-8. PubMed ID: 26561079
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Advances in biologic therapy for inflammatory bowel disease].
    Sostegni R; Pera A; Daperno M; Rocca R
    Recenti Prog Med; 2008 Jan; 99(1):10-8. PubMed ID: 18389866
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Pregnancy and medications in inflammatory bowel disease.
    Cao RH; Grimm MC
    Obstet Med; 2021 Mar; 14(1):4-11. PubMed ID: 33995565
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Biologic Therapies and Risk of Infection and Malignancy in Patients With Inflammatory Bowel Disease: A Systematic Review and Network Meta-analysis.
    Bonovas S; Fiorino G; Allocca M; Lytras T; Nikolopoulos GK; Peyrin-Biroulet L; Danese S
    Clin Gastroenterol Hepatol; 2016 Oct; 14(10):1385-1397.e10. PubMed ID: 27189910
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The effects of pregnancy on the pharmacokinetics of infliximab and adalimumab in inflammatory bowel disease.
    Seow CH; Leung Y; Vande Casteele N; Ehteshami Afshar E; Tanyingoh D; Bindra G; Stewart MJ; Beck PL; Kaplan GG; Ghosh S; Panaccione R
    Aliment Pharmacol Ther; 2017 May; 45(10):1329-1338. PubMed ID: 28318043
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Risks and benefits of biologic therapy for inflammatory bowel diseases.
    D'Haens G
    Gut; 2007 May; 56(5):725-32. PubMed ID: 17440187
    [No Abstract]   [Full Text] [Related]  

  • 47. Patient Understanding of the Risks and Benefits of Biologic Therapies in Inflammatory Bowel Disease: Insights from a Large-scale Analysis of Social Media Platforms.
    Martinez B; Dailey F; Almario CV; Keller MS; Desai M; Dupuy T; Mosadeghi S; Whitman C; Lasch K; Ursos L; Spiegel BMR
    Inflamm Bowel Dis; 2017 Jul; 23(7):1057-1064. PubMed ID: 28410343
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Emerging biologics in inflammatory bowel disease.
    Chan HC; Ng SC
    J Gastroenterol; 2017 Feb; 52(2):141-150. PubMed ID: 27832357
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The Evolving Evidence for Therapeutic Drug Monitoring of Monoclonal Antibodies in Inflammatory Bowel Disease.
    Sheasgreen C; Nguyen GC
    Curr Gastroenterol Rep; 2017 May; 19(5):19. PubMed ID: 28397129
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The potential beneficial role of faecal microbiota transplantation in diseases other than Clostridium difficile infection.
    Singh R; Nieuwdorp M; ten Berge IJ; Bemelman FJ; Geerlings SE
    Clin Microbiol Infect; 2014 Nov; 20(11):1119-25. PubMed ID: 25274035
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Nanotechnology in the Treatment of Inflammatory Bowel Disease.
    Giron F; Pastó A; Tasciotti E; Abraham BP
    Inflamm Bowel Dis; 2019 Nov; 25(12):1871-1880. PubMed ID: 31560054
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Inflammatory bowel disease and pregnancy.
    Maliszewska AM; Warska A; Cendrowski K; Sawicki W
    Ginekol Pol; 2017; 88(7):398-403. PubMed ID: 28819946
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Croatian consensus on the treatment of inflammatory bowel diseases with biologic therapy].
    Vucelić B; Cuković-Cavka S; Banić M; Bilić A; Borzan V; Duvnjak M; Katicić M; Kolacek S; Krznarić Z; Kujundzić M; Marusić M; Mihaljević S; Mijandrusić BS; Persić M; Simunić M; Skurla B; Stimac D; Tonkić A; Troskot B
    Acta Med Croatica; 2013 Apr; 67(2):75-87. PubMed ID: 24471291
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Analysis of Safety, Medical Resource Utilization, and Treatment Costs by Drug Class for Management of Inflammatory Bowel Disease in the United States Based on Insurance Claims Data.
    Long GH; Tatro AR; Oh YS; Reddy SR; Ananthakrishnan AN
    Adv Ther; 2019 Nov; 36(11):3079-3095. PubMed ID: 31562607
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Discussion on the biologic therapy of inflammatory bowel disease.
    Merger M; Herfarth H; Scholmerich J; Andus T; Färber L
    Gastroenterology; 2003 Jun; 124(7):2005-6. PubMed ID: 12812200
    [No Abstract]   [Full Text] [Related]  

  • 56. [Place of biologic therapy in the treatment of inflammatory bowel diseases and assessment of its efficacy].
    Krznarić Z; Stimac D; Franjić N; Kunović A; Kelecić DL
    Acta Med Croatica; 2013 Apr; 67(2):145-55. PubMed ID: 24471297
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Inflammatory bowel disease during pregnancy and childbirth].
    Závorová K
    Ceska Gynekol; 2017; 82(2):108-116. PubMed ID: 28585842
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Inflammatory bowel disease and pregnancy: report of 76 cases and review of the literature].
    Beniada A; Benoist G; Maurel J; Dreyfus M
    J Gynecol Obstet Biol Reprod (Paris); 2005 Oct; 34(6):581-8. PubMed ID: 16208201
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Modulation of sphingosine-1-phosphate in inflammatory bowel disease.
    Peyrin-Biroulet L; Christopher R; Behan D; Lassen C
    Autoimmun Rev; 2017 May; 16(5):495-503. PubMed ID: 28279838
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The risks and benefits of early immunosuppression and biological therapy.
    Sands BE
    Dig Dis; 2012; 30 Suppl 3():100-6. PubMed ID: 23295699
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.